Drug survival of secukinumab for moderate-to-severe plaque psoriasis

Lee, E.B.; Reynolds, Kelly A.; Pithadia, Deeti J.; Wu, Jianni

doi:10.1111/bjd.16572

Cited by 4 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Longer‐term, real‐world clinical data on secukinumab's survival based on patient profiles are presented. Our results show higher survival rates compared to those found in clinical trials . Previous studies have shown different survival rates .…”

Section: Resultscontrasting

confidence: 69%

“…On the other hand, Lee found that only 41.70% ( n = 48) of patients receiving secukinumab in their series did not require combined treatment or a change to their alternative therapy, therefore establishing the lowest survival rate published to date. Lee attributes the highest dropout rate to a longer follow‐up period in their series . Georgakopoulos et al .…”

Section: Introductionmentioning

confidence: 96%

“…Lee attributes the highest dropout rate to a longer follow‐up period in their series . Georgakopoulos et al . in their study ( n = 41) established a survival rate of 68.30% of patients adjusted to a 52‐week record with patients who maintained PASI 75 or PGA 0–1, with loss of efficacy being the main cause of discontinuation.…”

Section: Introductionmentioning

confidence: 96%

See 2 more Smart Citations

Drug survival, discontinuation rates, and safety profile of secukinumab in real‐world patients: a 152‐week, multicenter, retrospective study

Ruíz‐Villaverde

Rodriguez‐Fernandez‐Freire

Galán‐Gutiérrez

et al. 2020

Int J Dermatology

View full text Add to dashboard Cite

Background Psoriasis is a chronic systemic disease that requires long-term management.Despite data on follow-up studies going back 5 years, little is known about the condition's sustainability based on patient profiles. The aim of this study was to analyze drug survival and discontinuation rates for secukinumab treatment under real-world conditions. Patients and MethodsPatients with moderate-to-severe plaque psoriasis treated in the dermatology department of five Spanish medical centers between 2015 and 2019 were included in our retrospective study. Drug survival was assessed with Kaplan-Meier analysis plots and multivariate regression. Results In total, 171 treated patients were retrospectively recorded and analyzed for 152 weeks (37.40% had been diagnosed with psoriatic arthritis [PsA]). The discontinuation rate in the PsA group was 14.10% vs. 12.10% among those who had no PsA. The mean survival time of discontinuation was 63 weeks for PsA vs. 65 weeks for no PsA (P = 0.913). Secukinumab's estimated mean survival in PsA patients was 86% (estimated mean survival time 130 weeks) vs. 88% (estimated mean survival time of 133 weeks) in non-PsA patients (P = 0.676).Conclusion The mean survival time of patients in secukinumab treatment was comparable in all patient profiles and better than the data found in clinical trials and real-life studies. Figure 2Kaplan-Meier plot of drug survival for secukinumab over 152 weeks according to: (a) psoriasis duration in years (less than 10 years, between 10 and 20 years and more than 20 years from PsO was diagnosed), (b) PASI basal (≤10, >10 ≤20, and >20), (c) bionaïve patients and non-bio-naïve patients (those previously treated with one or more biologics), and (d) according to BMI (≥18.99 ≤24.99, >25.00, ≤29.99, and ≥30). Censored patients (active) were defined as those who continued treatment. Noncensored patients (event) were those who interrupted treatment because of any of the above-mentioned causes [Colour figure can be viewed at wileyonlinelibrary.com] Pharmacology and Therapeutics Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients Ruiz-Villaverde et al. 638

show abstract

Section: Resultscontrasting

confidence: 69%

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Drug survival, discontinuation rates, and safety profile of secukinumab in real‐world patients: a 152‐week, multicenter, retrospective study

Ruíz‐Villaverde

Rodriguez‐Fernandez‐Freire

Galán‐Gutiérrez

et al. 2020

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Despite the availability of various biologics, physicians observe a disturbingly high burden of non-response or loss of response. [13][14][15][16][45][46][47][48] As the introduction of biologics has shifted the golden standard from PASI75 to PASI90 and even PASI100, 49 it is possible to treat patients ambitiously and manage the disease in such a way that proper responses are maintained during treatment. Strict follow-up of clinical response as postulated in treat-to-target can enhance effective use of these expensive drugs in patients with moderateto-severe psoriasis.…”

Section: Discussionmentioning

confidence: 99%

“…The result, a multidimensional target consisting of both physician‐reported outcome and PRO, reflects the reality and complexity of psoriasis and therefore guides treatment decisions with sufficient patient involvement. Despite the availability of various biologics, physicians observe a disturbingly high burden of non‐response or loss of response . As the introduction of biologics has shifted the golden standard from PASI75 to PASI90 and even PASI100, it is possible to treat patients ambitiously and manage the disease in such a way that proper responses are maintained during treatment.…”

Section: Discussionmentioning

confidence: 99%

A Belgian consensus on the definition of a treat‐to‐target outcome set in psoriasis management

Grine

Brassinne

Ghislain

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Objective Treat‐to‐target (T2T) is an algorithm to reach a predefined outcome. Here, we define a T2T outcome for moderate‐to‐severe psoriasis vulgaris. Methods Briefly, the study included a literature review, discussions with key opinion leaders, recruitment of additional dermatologists with experience in managing moderate‐to‐severe psoriasis, 3 eDelphi survey rounds and a patient focus group. Relevant topics were selected during discussions prior to the survey for the statements. Surveys were based on the eDelphi methodology for consensus‐building using a series of statements. Consensus was defined as at least 80% of participants agreeing. A psoriasis patient focus group provided feedback on topic selection and outcome. Results A total of 5 discussions were held, and 3 eDelphi rounds were conducted with an average of 19 participants per round. The T2T outcome was set assuming shared decision between patient and dermatologist, awareness and referral for comorbidities by the dermatologist and appropriate treatment adherence by the patient. We defined ‘ideal’ and ‘acceptable’ targets; the latter referring to conditions restricting certain drugs. The T2T outcome was multidimensional, including ≥ ΔPASI90/75 or PGA ≤ 1, itch VAS score ≤ 1, absence of disturbing lesions, DLQI ≤ 1/3, incapacity daily functioning VAS score ≤ 1, safety ≤ mild side‐effects and full/mild tolerability of treatment for the ideal and acceptable target, respectively. Finally, time to achieve the T2T outcome was set at 12 weeks after initiation for all treatments. At all times, safety should not exceed the presence of mild side‐effects. Conclusion With this novel T2T composite outcome for psoriasis, clinicians and patients can make shared decisions on the treatment goals they envisage, as a guidance for future treatment steps – leading to a tight control management of the disease.

show abstract